Boston Scientific’s Lotus TAVR Gets Boost From REPRISE II And UK Series
This article was originally published in Clinica
Executive Summary
Boston Scientific’s Lotus transcatheter aortic valve replacement system demonstrated favorable outcomes in the REPRISE II trial and a 228-case series in the UK.